An2 Therapeutics, INC. (ANTX) — SEC Filings

Overview

An2 Therapeutics, INC. (ANTX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a EFFECT filed on Apr 21, 2026: AN2 Therapeutics, Inc. filed an EFFECT form with the SEC on April 21, 2026, indicating the effectiveness of a registration statement. The filing, with accession number 9999999995-26-001256, relates to Act 33 and has file number 333-294956.

Sentiment Summary

Across 41 filings, the sentiment breakdown is: 2 bearish, 37 neutral, 2 mixed. The dominant filing sentiment for An2 Therapeutics, INC. is neutral.

Filing Type Overview

An2 Therapeutics, INC. (ANTX) has filed 5 4, 1 EFFECT, 12 8-K, 5 10-Q, 2 DEF 14A, 10 SC 13G/A, 4 SC 13G, 1 10-K/A, 1 10-K with the SEC between Feb 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (41)

• AN2 Therapeutics SEC Filing Effectiveness Notice — EFFECT · Apr 21, 2026 Risk: low
  AN2 Therapeutics, Inc. filed an EFFECT form with the SEC on April 21, 2026, indicating the effectiveness of a registration statement. The filing, with accession
• 8-K Filing — 8-K · Apr 9, 2026
• AN2 Therapeutics: Incomplete Form 4 Filed for Sanjay Chanda — 4 · Mar 23, 2026
  This Form 4 filing for AN2 Therapeutics, Inc. (AN2) indicates a change in beneficial ownership for Sanjay Chanda, a reporting person, as of March 19, 2026. Whil
• AN2 Therapeutics: Form 4 Filed for Margaret M. FitzPatrick — 4 · Mar 23, 2026
  This Form 4 filing, dated March 23, 2026, indicates a change in beneficial ownership for AN2 Therapeutics, Inc. (AN2T). While the filing itself doesn't detail s
• AN2 Therapeutics: Insider Stephanie Wong Files Form 4 — 4 · Mar 23, 2026
  This Form 4 filing, dated March 23, 2026, indicates a change in beneficial ownership for Stephanie Wong, a reporting person for AN2 Therapeutics, Inc. While the
• AN2 Therapeutics: Insider Ownership Change Filed, Details Pending — 4 · Mar 23, 2026
  This Form 4 filing, dated March 23, 2026, indicates a change in beneficial ownership for Joseph S. Zakrzewski, a reporting person for AN2 Therapeutics, Inc. (AN
• AN2 Therapeutics: Melvin K. Spigelman Files Form 4 — 4 · Mar 23, 2026
  This Form 4 filing indicates a change in beneficial ownership for Melvin K. Spigelman, a reporting person for AN2 Therapeutics, Inc. (AN2). While the filing det
• ANTX Narrows Q3 Loss, R&D Spend Halved Amid Cash Burn — 10-Q · Nov 12, 2025 Risk: medium
  AN2 Therapeutics, Inc. (ANTX) reported a net loss of $9.353 million for the three months ended September 30, 2025, an improvement from a net loss of $12.747 mil
• ANTX Narrows Losses Amid Sharp R&D Spending Cut — 10-Q · Aug 12, 2025 Risk: medium
  AN2 Therapeutics, Inc. (ANTX) reported a net loss of $6.46 million for the three months ended June 30, 2025, a significant improvement from the $14.44 million n
• AN2 Therapeutics Reports Unregistered Equity Sales — 8-K · Jun 20, 2025 Risk: medium
  AN2 Therapeutics, Inc. filed an 8-K on June 20, 2025, reporting unregistered sales of equity securities that occurred on June 17, 2025. The filing also includes
• 8-K Filing — 8-K · Jun 11, 2025
• AN2 Therapeutics Files 8-K on Shareholder Vote Matters — 8-K · May 27, 2025 Risk: low
  AN2 Therapeutics, Inc. filed an 8-K on May 27, 2025, reporting on matters submitted to a vote of security holders as of May 22, 2025. The filing details the com
• AN2 Therapeutics Files Q1 2025 10-Q — 10-Q · May 13, 2025 Risk: medium
  AN2 Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company's primary focus remains on its pharmaceutical preparations business. Key
• AN2 Therapeutics Files 8-K Report — 8-K · May 1, 2025 Risk: low
  On May 1, 2025, AN2 Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or
• AN2 Therapeutics Files 2025 Proxy Statement — DEF 14A · Apr 10, 2025 Risk: low
  AN2 Therapeutics, Inc. filed its definitive proxy statement on April 10, 2025, for the fiscal year ending December 31, 2024. The filing, designated as DEF 14A,
• AN2 Therapeutics Files 8-K on Operations & Financials — 8-K · Mar 25, 2025 Risk: low
  AN2 Therapeutics, Inc. filed an 8-K on March 25, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhib
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 13, 2024
• AN2 Therapeutics Files Q3 2024 10-Q — 10-Q · Nov 13, 2024 Risk: medium
  AN2 Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates. Key financial
• AN2 Therapeutics Appoints New Director, Discloses Officer Compensation — 8-K · Nov 5, 2024 Risk: low
  AN2 Therapeutics, Inc. announced on November 4, 2024, a change in its board of directors. Specifically, Dr. Richard S. Gaynor has been appointed as a new dir
• SC 13G/A Filing — SC 13G/A · Aug 28, 2024
• AN2 Therapeutics Files 8-K: Material Agreement — 8-K · Aug 19, 2024 Risk: medium
  AN2 Therapeutics, Inc. announced on August 15, 2024, that it entered into a Material Definitive Agreement. The filing also indicates modifications to the rights
• SC 13G/A Filing — SC 13G/A · Aug 14, 2024
• SC 13G/A Filing — SC 13G/A · Aug 13, 2024
• AN2 Therapeutics Q2 2024 Update — 10-Q · Aug 13, 2024 Risk: medium
  AN2 Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial condition and results of operations, including
• SC 13G Filing — SC 13G · Aug 12, 2024
• AN2 Therapeutics Announces Director Changes and Compensatory Arrangements — 8-K · Aug 8, 2024 Risk: medium
  On August 7, 2024, AN2 Therapeutics, Inc. filed an 8-K report detailing several key events. The company announced the departure of Director Dr. Jonathan Leff an
• SC 13G Filing — SC 13G · Jul 3, 2024
• AN2 Therapeutics Files 8-K on Security Holder Votes & Financials — 8-K · Jun 24, 2024 Risk: low
  AN2 Therapeutics, Inc. filed an 8-K on June 24, 2024, reporting on matters submitted to a vote of security holders and financial statements. The filing date for
• AN2 Therapeutics Files Amendment No. 1 to Annual Report on Form 10-K — 10-K/A · May 14, 2024 Risk: low
  AN2 Therapeutics, Inc. (ANTX) filed a Amended Annual Report (10-K/A) with the SEC on May 14, 2024. AN2 Therapeutics, Inc. filed an amendment (10-K/A) to its ann
• AN2 Therapeutics, Inc. Announces 2024 Annual Meeting of Stockholders on June 19, 2024 — DEF 14A · Apr 26, 2024 Risk: low
  AN2 Therapeutics, Inc. (ANTX) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. AN2 Therapeutics, Inc. will hold its 2024 Annual Meeting of Stoc
• SC 13G Filing — SC 13G · Apr 10, 2024
• AN2 Therapeutics Files 2023 Annual Report on Form 10-K — 10-K · Mar 29, 2024 Risk: medium
  AN2 Therapeutics, Inc. (ANTX) filed a Annual Report (10-K) with the SEC on March 29, 2024. AN2 Therapeutics, Inc. filed its annual report for the fiscal year en
• AN2 Therapeutics Files 8-K on Financials — 8-K · Mar 28, 2024 Risk: low
  On March 28, 2024, AN2 Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as wel
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G Filing — SC 13G · Feb 13, 2024
• Janus Henderson Cuts AN2 Therapeutics Stake to Zero Voting Shares — SC 13G/A · Feb 12, 2024 Risk: medium
  Janus Henderson Group plc, a global investment manager, filed an amended SC 13G/A on February 12, 2024, indicating a change in their beneficial ownership of AN2
• AN2 Therapeutics Files Routine 8-K for 'Other Events' — 8-K · Feb 12, 2024 Risk: low
  AN2 Therapeutics, Inc. filed an 8-K on February 12, 2024, to report an "Other Event." This filing primarily serves to update the public record regarding the com
• Adjuvant Capital Reduces AN2 Therapeutics Stake, Files SC 13G/A — SC 13G/A · Feb 9, 2024 Risk: medium
  Adjuvant Global Health Technology Fund, L.P. filed an amended SC 13G/A on February 9, 2024, indicating a change in their ownership of AN2 Therapeutics, Inc. com

Frequently Asked Questions